Pircher, C.
143  Ergebnisse:
Personensuche X
?
5

P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Pati..:

Proto, C. ; Chiaruttini, M.V. ; Prelaj, A....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S119-S120 , 2022
 
?
6

EP07.01-021 Clinical and Biochemical Profiling of Pleural M..:

Occhipinti, M. ; Tacchetto, A. ; Beninato, T....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S322-S323 , 2022
 
?
7

MA10.07 Phase II Trial of Sunitinib in Patients with Type B..:

Proto, C. ; Galli, G. ; Manglaviti, S....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S79-S80 , 2022
 
?
8

EP08.01-006 Using Real World data to build effective predic..:

prelaj, A. ; Galli, E.G. ; Pesenti, M....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S337-S338 , 2022
 
?
10

Regulation of Complement C3 Expression by the Bile Acid Rec..:

Li, Jiali ; Pircher, Parinaz C. ; Schulman, Ira G..
Journal of Biological Chemistry.  280 (2005)  9 - p. 7427-7434 , 2005
 
?
 
?
12

Optimal Choice of Adjuvant Treatment for Renal Cell Carcino..:

Bottiglieri A ; Sepe P ; Stellato M...
https://www.dovepress.com/optimal-choice-of-adjuvant-treatment-for-renal-cell-carcinoma-followin-peer-reviewed-fulltext-article-CMAR.  , 2022
 
?
14

Beyond first-line immunotherapy: Potential therapeutic stra..:

Prelaj A ; Pircher C. C ; Massa G...
info:eu-repo/semantics/altIdentifier/pmid/33803958.  , 2021
 
?
15

Beyond first-line immunotherapy: Potential therapeutic stra..:

Prelaj A ; Pircher C. C ; Massa G...
info:eu-repo/semantics/altIdentifier/pmid/33803958.  , 2021
 
1-15